Qualigen Therapeutics Inc
Change company Symbol lookup
Select an option...
QLGN Qualigen Therapeutics Inc
JOFF JOFF Fintech Acquisition Corp
IR Ingersoll Rand Inc
TGT Target Corp
CCLP CSI Compressco LP
BIOT Biotech Acquisition Co
XNXNX Nuveen New York Select Tax Free Income Portfolio
DHHC DiamondHead Holdings Corp
WFC Wells Fargo & Co
SFNC Simmons First National Corp
Go

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Health Care : Biotechnology | Small Cap Value
Company profile

Qualigen Therapeutics, Inc. is a diversified life sciences company focused on developing treatments for adult and pediatric cancer. The Company's cancer therapeutics pipeline includes QN-302, QN-247 and RAS-F. QN-302 compound is a small molecule genomic quadruplex (G4) selective transcription inhibitor with binding affinity to G4s prevalent in cancer cells. QN-247 is a deoxyribonucleic acid (DNA) coated gold nanoparticle cancer drug candidate to target various types of cancer. RAS-F is a family of rat sarcoma virus (RAS) oncogene protein-protein interaction inhibitor small molecules for preventing mutated RAS genes’ proteins from binding to their effector proteins and preventing this binding to stop tumor growth, especially in RAS-driven tumors such as pancreatic, colorectal and lung cancers. Its pipeline also includes QN-165, a drug candidate for treating COVID-19 and other viral-based infectious diseases.

Closing Price
$1.51
Day's Change
-0.10 (-6.21%)
Bid
--
Ask
--
B/A Size
--
Day's High
1.62
Day's Low
1.51
Volume
(Light)
Volume:
18,779

10-day average volume:
59,376
18,779

Unable to locate that news article. Back to news results

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.